The company's P/E ratio is N/A and market capitalization is 2.11B. They now have an outperform rating on the stock. UBS AG downgraded Mallinckrodt PLC from a "buy" rating to a "neutral" rating and set a $24.00 price target on the stock.in a research report on Monday. Finally, Oppenheimer Holdings, Inc. set a $70.00 price target on Mallinckrodt PLC and gave the stock a "buy" rating in a research report on Tuesday, August 8th. The firm earned "Buy" rating on Wednesday, August 16 by BMO Capital Markets. They presently have a $55.00 price target on the stock. The consensus recommendation for stock is 2.30. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the stock. $71.84's average target is 230.15% above currents $21.76 stock price. Riverhead Cap Mgmt Limited Liability Company has 0.07% invested in Mallinckrodt PLC (NYSE:MNK) for 31,105 shares. BMO Capital Markets maintained the stock with "Buy" rating in Thursday, October 5 report. The share last price represents downtick move of -68.06% in value from company's 52-Week high price and shows 14.53% above change in value from its 52-Week low price. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.38 and a quick ratio of 1.05.
Mallinckrodt PLC (NYSE:MNK) opened at $21.90 on Tuesday. The company reported $1.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.80 by $0.17. The company had revenue of $793.90 million during the quarter, compared to analyst estimates of $808.93 million. Municipal Employees Retirement System of MI now owns 5,640 shares of the company's stock valued at $253,000 after acquiring an additional 1,110 shares in the last quarter. Mallinckrodt Public Limited Company's average EBITDA per Share Growth Rate was -28.2 percent during the past 12 months. If you are viewing this article on another website, it was stolen and republished in violation of US & worldwide trademark and copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/11/14/mallinckrodt-plc-mnk-vp-steven-j-romano-acquires-2000-shares-of-stock.html. The shares were purchased at an average cost of $39.63 per share, for a total transaction of $50,726.40. Active and passive investors always require every bit of information available regarding his chosen security and this include keeping close watch on fundamental and technical data.
The company is up by 1.88% at $22.17 and has one of the biggest price gains of the day.
Several hedge funds and other institutional investors have recently modified their holdings of the company. OppenheimerFunds Inc. boosted its holdings in Mallinckrodt PLC by 23.1% in the 1st quarter. To cut down amount of noise on price chart, shares of firm has 20 days moving average price of -25.52% from last close price of 21.90 and act as support or resistance of price limit. Quantbot Technologies L P has invested 0.04% in Mallinckrodt PLC (NYSE:MNK). American International Group Inc now owns 198,807 shares with a value of $7,429,000. Sterling Capital Management LLC acquired a new stake in shares of Mallinckrodt PLC during the 2nd quarter valued at $204,000. Teachers Advisors LLC boosted its holdings in Mallinckrodt PLC by 4.3% in the 1st quarter. Teachers Advisors LLC now owns 187,286 shares of the company's stock worth $8,347,000 after purchasing an additional 7,753 shares in the last quarter. Ameriprise Financial Inc. now owns 1,987,196 shares of the company's stock worth $74,260,000 after buying an additional 49,752 shares during the period. Commonwealth Natl Bank Of Australia invested in 616 shares or 0% of the stock.
It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The Firm focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.